ArticleWorld journal of diabetes2025
Increased tumor necrosis factor-receptor superfamily plasma levels are associated with early renal or retinal involvement in intermediate hyperglycemia.
Article in World journal of diabetes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes and its associated microvascular complications, such as nephropathy and retinopathy, significantly impact global health. These complications often begin in the prediabetic stage, emphasizing the importance of early detection and intervention. Inflammatory pathways are key contributors to these conditions, and recent research has identified members of the tumor necrosis factor (TNF) receptor superfamily as potential biomarkers. However, their association with renal and retinal dysfunction in individuals with intermediate hyperglycemia (IH) remains underexplored. The Early Prevention of Diabetes Complications (ePREDICE) trial provides a valuable cohort to investigate these associations and improve risk assessment strategies.
aimTo identify inflammatory biomarkers associated with early renal and retinal dysfunction in individuals with IH. Specifically, we evaluate the diagnostic and prognostic potential of TNF receptor superfamily members [TNF receptor 1 (TNF-R1), TNF receptor 2 (TNF-R2)], T-cell immunoglobulin and mucin domain 3 (TIM-3)/
methodsA cross-sectional analysis of 967 individuals with IH from the ePREDICE trial was conducted. Participants underwent comprehensive anthropometric and biochemical assessments. Key inflammatory biomarkers, including TNF-R1, TNF-R2, TIM-3/
resultsTNF-R1, TNF-R2, and TIM-3/
conclusionOur findings highlight the potential of TNF receptor superfamily members as biomarkers for early-stage renal and retinal complications in individuals with IH. Their integration into clinical screening protocols could facilitate earlier detection, improving patient stratification and personalized management strategies. Further longitudinal studies are necessary to validate their predictive value and potential for guiding therapeutic interventions in IH and early diabetes management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.